Biohackers and longevity clinics claim peptides are a side-effect-free sniper rifle for fat loss and injury recovery, but the reality is often buried in failed clinical trials and regulatory bans. Many popular compounds like BPC-157 have never undergone a single randomized controlled trial in humans, despite their reputation for Wolverine-like healing. This episode dismantles the hype surrounding the gray market, exposing the significant risks of immunogenicity and heavy metal contamination. Learn why modern load management and evidence-based medicine beat a research chemical bought with Bitcoin every time.

Next Steps

For evidence-based resistance training programs: barbellmedicine.com/training-programs

For individualized medical and training consultation: barbellmedicine.com/coaching

Explore our full library of articles on health and performance: barbellmedicine.com/resources

To join Barbell Medicine Plus and get ad-free listening, product discounts, exclusive content, and more: https://barbellmedicine.supercast.com/

Key Points

The FDA Category 2 Crackdown: Federal regulators restricted many peptides because of the risk of immunogenicity where the body creates antibodies that attack its own proteins.
BPC-157 Has Zero Human Data: Despite being marketed for tendon repair, there is not a single published human randomized controlled trial for this molecule.
The MK-677 Prediabetes Tax: While it increases lean mass, human trials show zero improvement in strength or power while frequently causing insulin resistance.
Retatrutide as the Weight Loss Godzilla: This triple agonist is achieving nearly 29 percent weight loss in trials by increasing energy expenditure through thermogenesis.
Sourcing and Safety Realities: A study of 44 research chemicals found that only 18 actually contained the labeled compound, with many containing heavy metals.
The 40-Amino-Acid Rule: The legal distinction between a peptide and a protein is based on size, which dictates how the FDA regulates these substances and how your body absorbs them.

Timestamps

00:03 Intro: The CJC-1295 Heart Attack Case
05:39 Defining a Peptide: The 40-Amino-Acid Bright Line
15:14 GH Secretagogues: CJC-1295 and Ipamorelin
23:51 MK-677: The Oral Hunger Mimetic and Prediabetes Risk
32:56 BPC-157 and the Lack of Human Data
38:12 Immunogenicity: Why the FDA Banned BPC-157
49:46 Retatrutide: The Triple Agonist Weight Loss Godzilla
01:11:24 Summary: Peptides vs. Anabolic Steroids
01:16:12 The Sourcing Spectrum: Pharmaceutical vs. Research Chemicals

Clinical Pearls

Use load management and progressive resistance training as the primary intervention for tendon and muscle injuries rather than unproven peptides.
If choosing to use metabolic modulators, monitor fasting blood glucose and insulin sensitivity to avoid drug-induced prediabetes or metabolic dysfunction.
Avoid the research chemical gray market entirely due to the high prevalence of under-dosing, contamination, and incorrect active ingredients found in third-party testing.

Resources

Our Sponsors:
* Check out Factor: https://factormeals.com/bbm50off
* Check out Quince: https://quince.com/BBM

Support this podcast at — https://redcircle.com/barbell-medicine-podcast/donations

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy

24. Theo Francken: “Trump is het ideale excuus om niet naar eigen zwaktes te kijken”

Het Rapport van de Wetstraat

Einde

The AI-powered Podcast Player